Brigatinib CAS 1197953-54-0 Ịdị ọcha> 99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd bụ onye na-emepụta Brigatinib (AP-26113) (CAS: 1197953-54-0) nwere oke mma.Ruifu Chemical nwere ike ịnye nnyefe zuru ụwa ọnụ, ọnụahịa asọmpi, ọrụ magburu onwe ya, obere na nnukwu ọnụọgụ dị.Ịzụta Brigatinib,Please contact: alvin@ruifuchem.com
Aha Chemical | Brigatinib |
Ụdị okwu | AP26113;AP-26113;5-Chloro-N4-[2- (Dimethylphosphinyl) phenyl] -N2-[2-Methoxy-4-[4- (4-Methyl-1-Piperazinyl) -1-Piperidinyl] phenyl] -2,4-Pyrimidinediamine |
Ọnọdụ Ahịa | Na ngwaahịa, Mmepụta Azụmahịa |
Nọmba CAS | 1197953-54-0 |
Usoro ihe omimi | C29H39ClN7O2P |
Ibu molekụla | 584.09 g/mol |
Ebe Na-agbaze | > 203 ℃ (Dec.) |
Njupụta | 1.31±0.10 g/cm3 |
COA & MSDS | Dị |
Mmalite | Shanghai, China |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta | Nsonaazụ |
Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ | Na-akwado |
Ụzọ ịdị ọcha / nyocha | > 99.0% (HPLC) | 99.26% |
Oke.Otu adịghị ọcha | <1.00% | 0.25% |
Ọnwụ na ihicha | <1.00% | 0.27% |
Spectrum infrared | Nkwekọ na Structure | Na-akwado |
1H NMR Spectrum | Nkwekọ na Structure | Na-akwado |
Mmechi | A nwalela ngwaahịa a wee kwado nkọwa ndị enyere |
ngwugwu:Fluorinated Bottle, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Debe akpa ahụ nke ọma ma debe ya n'ụlọ nkwakọba ihe dị jụụ, kpọrọ nkụ na nke ikuku na-ekpo ọkụ n'ebe ihe na-adabaghị adaba.Chebe site na ìhè na mmiri mmiri.
Mbupu:Jiri ikuku na-ebuga ụwa niile site na FedEx / DHL Express.Nye nnyefe ngwa ngwa na ntụkwasị obi.
Kedu ka esi azụta?Biko kpọtụrụDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Ahụmịhe afọ 15?Anyị nwere ihe karịrị 15 afọ nke ahụmahụ na mmepụta na mbupụ nke a dịgasị iche iche nke elu mma pharmaceutical intermediates ma ọ bụ ezi kemịkal.
Isi ahịa?Na-ere ahịa ụlọ, North America, Europe, India, Korea, Japanese, Australia, wdg.
Uru?Ogo kachasị elu, ọnụ ahịa dị ọnụ ala, ọrụ ọkachamara na nkwado teknụzụ, nnyefe ngwa ngwa.
OgoNkwenye?Usoro njikwa mma siri ike.Ngwá ọrụ ọkachamara maka nyocha gụnyere NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, wdg.
Ihe atụ?Ọtụtụ ngwaahịa na-enye ihe nlele efu maka nyocha dị mma, ndị ahịa kwesịrị ịkwụ ụgwọ mbupu.
Nyocha ụlọ ọrụ?Nnabata nyocha ụlọ ọrụ.Biko mee oge oge tupu oge eruo.
MOQ?Enweghị MOQ.A na-anabata obere usoro.
Oge Mbuga ozi? Ọ bụrụ n'ime ngwaahịa, ekwenyere nnyefe ụbọchị atọ.
Ụgbọ njem?Site Express (FedEx, DHL), nke ikuku, site n'oké osimiri.
Akwụkwọ?Mgbe ọrụ ahịa gasịrị: COA, MOA, ROS, MSDS, wdg nwere ike ịnye.
Synthesis omenala?Nwere ike ịnye ọrụ nhazi ahaziri iche ka ọ dabara mkpa nyocha gị nke ọma.
Usoro ịkwụ ụgwọ?A ga-ebu ụzọ ziga akwụkwọ ọnụahịa Proforma mgbe nkwenye nke iwu, kpuchiri ozi ụlọ akụ anyị.Ịkwụ ụgwọ site na T/T (Telex Nyefee), PayPal, Western Union, wdg.
Brigatinib (AP-26113) (CAS: 1197953-54-0) bụ nyocha nke obere mkpụrụ ndụ ezubere iche maka ọgwụgwọ ọrịa kansa nke ARIAD Pharmaceuticals, Inc. Brigatinib bụ ọgwụ eji agwọ ọrịa kansa nke na-egbochi onye na-anabata ihe na-eto eto epidermal (EGFR) na anaplastic lymphoma kinase (ALK).Brigatinib bụ agonist na-ahọrọ megide ọdịiche nke EGFR na-emegide ụdị mutant anụ ọhịa.Ọgwụ ahụ na-egosipụtakwa nhọrọ megide mkpụrụ ndụ ihe nketa ALK-EML4, nke bụ akụkụ dị mkpa nke mgbanwe nke parenchyma nku ume nwere ike ime.Edere Brigatinib maka ndị ọrịa nwere mkpụrụ ndụ ihe nketa na-adịghị mma yana mgbe ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) anaghị anabata njikwa ọgwụ ndị ọzọ.A na-ekewa Brigatinib dị ka onye na-egbochi kinase, nke usoro ya na-agụnye ịkwụsị ọrụ nke protein ndị na-adịghị mma nke na-eme ka mmụba nke mkpụrụ ndụ cancer.
A na-edenye Brigatinib (CAS: 1197953-54-0) maka ndị ọrịa nwere ụdị NSCLC dị iche iche nke gbasaara n'akụkụ dị iche iche nke ahụ ndị mmadụ na-ejibu ọgwụ ọrịa cancer ndị ọzọ dị ka Crizotinib, na ọnọdụ ha adịla njọ. ma ọ bụ ha na-egosi ntakịrị ihe ịrịba ama nke mmelite.A na-enyocha ya nke ọma maka ọgwụgwọ ya na ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) ebe ALK na-arụ ọrụ yana ngbanwe EGFP na-emekarị.
Brigatinib (AP-26113) (CAS: 1197953-54-0) bụ ihe mgbochi ọgbọ ọhụrụ nke tyrosine kinase, na-egosi nrụpụta dị ukwuu na ALK + metastatic NSCLC.Na August 30, 2016, United States FDA nyere bugtinib dị ka ọgwụgwọ ọganihu na ọgwụ na-adịghị ahụkebe maka ALK + NSCLC na ndị ọrịa mepụtara ma ọ bụ enweghị ike ịnagide Crizotinib, ọgwụgwọ ALK + NSCLC nke ọgbọ mbụ.Nye nlebanya ngwa ndetu ụzọ ma kwe ka etinye data ngwa n'usoro ntụgharị.FDA kwadoro Bugtinib na Eprel 28, 2017, n'okpuru aha ahia Alunbrigtm.